REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,770.00
Bid: 1,770.00
Ask: 1,770.50
Change: 9.00 (0.51%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,775.50
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: Shell Overtakes BP Amid Mixed London Trading

Wed, 30th Apr 2014 09:47

LONDON (Alliance News) - UK stocks trade mixed Wednesday, as investors await a raft of releases from the US and after the preliminary reading of eurozone consumer price inflation accelerated from a more than four-year low, but still missed forecasts.

By mid-morning, the FTSE 100 is marginally higher at 6,773.55, the FTSE 250 is down 0.4% at 15,838.4, and the AIM All-Share is up 0.6% at 820.65.

It is a similar story in Europe, where the DAX 30 in Frankfurt is up 0.1%, while the CAC 40 in Paris is down 0.2%.

In data just released, consumer price inflation in the euro area increased to 0.7% in April from 0.5% in March. Although this meant CPI edged up from its 2009 lows, it fell short of the 0.8% that economists had been expecting.

"The ship is starting to sink and time is running out for the European Central Bank to divert a 1990s Japanese-style bout of deflation," says Dennis de Jong, managing director at UFXMarkets. "Inflation simply isn?t rising quick enough and stimulus is required, be it through the introduction of quantitative easing or negative interest rates. (ECB President) Mario Draghi has said that he is prepared to take emergency measures, but now is the time for action rather than words.

The euro dropped to a three-week low against the dollar in the aftermath of the data, before almost immediately regaining its losses, and then some. The single currency currently trades at USD1.3827, while the pound trades at USD1.6817.

Within UK equities, oil and gas producers are big risers, with the FTSE 350 sector up 2.3%.

Royal Dutch Shell is the biggest riser in the FTSE 100, up 4.4%. The oil and gas giant, which has now overtaken BP as the second largest company in the FTSE 100 by market capitalisation after HSBC Holdings, said its earnings almost halved in the first quarter of the year, as it wrote down some of the value of its refineries in Europe and Asia due to declining refining margins and as its production fell.

However, like its peer BP on Tuesday, Shell said it would pay a higher dividend for the quarter as it returns some of the funds from its asset sale programme to its shareholders.

Tullow Oil is another big blue-chip riser, up 3.2%. The company has pushed ahead with the sale of its UK gas assets in the southern North Sea, selling stakes in two assets to AIM-listed Faroe Petroleum for USD75.6 million plus a royalty on developments at one of the assets.

In the FTSE 250, Heritage Oil is the leading gainer. The firm's shares are up 22% after it said it had recommended shareholders accept a GBP924 million takeover offer from Al Mirqab Capital, an investment vehicle controlled by the royal family of Qatar.

Away from the oil and gas producers, Rolls-Royce is big winner Wednesday, up 2.6%. Shares in the company jumped after it said late on Tuesday that it is in talks with Germany's Siemens AG about a possible sale of its energy gas turbine and compressor business.

At the other end of the spectrum, Standard Life is one of the biggest fallers in the FTSE 100, currently down 1.7%. The Edinburgh-based long-term savings and investments provider said its assets under administration increased 1.5% in the first quarter driven by net inflows, but said recent changes to annuity regulations in the UK resulted in a reduction in UK annuity sales of around 50%.

However, the five heaviest fallers in the index are all companies that have gone ex-dividend Wednesday, meaning new buyers no longer qualify for the latest dividend payout from each of the companies. Tesco is down 3.5%, Admiral Group is down 3.4%, Reed Elsevier is down 3.1%, William Hill is down 2.8%, and Weir Group is down 1.9%

Still to come in the corporate calendar Wednesday, GlaxoSmithKline is due to release its first quarter results at 1100 GMT. Ahead of the release, the pharmaceutical giant's shares are down 1.3%.

In the data calendar, Italian produce price index numbers are released at 1000 GMT.

In the US, the Mortgage Bankers Association releases its MBA mortgages applications data at 1100 GMT. Shortly after, the ADP employment change figure for April, released at 1215 GMT, is expected to report that the world's largest economy added 210,000 new jobs in April, up from the 191,000 added in March. The preliminary reading of US first quarter GDP is published at 1230 GMT. Expectations are for US GDP to have decelerated to annualised reading of 1.2%, down from 2.6%. The Chicago purchasing managers' index is released at 1345 GMT.

Later in the day, the US Federal Open Market Committee publishes its latest interest rate and monetary policy decisions at 1800 GMT.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.